Vietnam ASF Vaccine Q3 Rollout Lifts Animal Vaccines Market

Vietnam Sets Q3 2026 Release for African Swine Fever Vaccine, Supporting Asia-Pacific Animal Vaccines Demand 

MANILA, Philippines — June 24, 2026 — Vietnam's African swine fever (ASF) vaccine is on track for commercial release in the third quarter of 2026, a development expected to support livestock-sector recovery across Southeast Asia and reinforce demand within the global Animal Vaccines Market. The progress is significant because ASF has caused sustained losses across regional swine herds, and an authorized vaccine addresses one of the most economically damaging animal disease threats facing producers in Asia-Pacific. 

Main Development 

The AVAC live attenuated ASF vaccine developed in Vietnam may be issued for broader commercial use by the third quarter of the year, supporting efforts to rebuild swine production capacity affected by ASF outbreaks. 

The anticipated rollout follows Vietnam's earlier role as a global pioneer in ASF vaccine commercialization, positioning the country's developers at the forefront of a category that has drawn advanced clinical programs from leading multinational animal health companies. 

Regional regulators and producers continue to prioritize ASF prevention as a structural pillar of biosecurity, food security, and herd-management strategies across swine-producing economies in Southeast Asia. 

Key Highlights: 

• Vietnam's AVAC live attenuated ASF vaccine is targeted for third-quarter 2026 release. 

• The rollout supports livestock-sector recovery from ASF outbreaks across the region. 

• The global animal vaccines market was valued at USD 13.4 billion in 2026, according to NMSC. 

• The market is projected to reach USD 22.4 billion by 2035 at a CAGR of 5.8%. 

Analyst Insight: 

According to analysts at Next Move Strategy Consulting, the successful development and commercial launch of ASF vaccines represents the single largest value-creation event currently unfolding in the animal vaccines market, with a globally authorized ASF vaccine from a major company potentially generating peak annual revenues of USD 1 billion or more. 

NMSC analysts note that Asia-Pacific is the fastest-growing major region in the market at a CAGR of 7.3% from 2026 to 2035, driven in part by government livestock disease control programs and the region's role in pioneering ASF vaccine deployment. 

Industry Outlook: 

A confirmed third-quarter release in Vietnam would advance regional disease-control capacity and reinforce the structural shift toward preventive biological solutions over reactive treatment approaches. As regulators, producers, and animal health companies continue to prioritize ASF prevention, sustained demand for both established and next-generation vaccine platforms is expected to underpin long-term market growth across Asia-Pacific. 

Source: BusinessWorld Online 

Prepared By: Sanyukta Deb 

For More Information – Download FREE Sample on Animal Vaccines Market Report